Microsporidiosis secondary prevention: Difference between revisions
Jump to navigation
Jump to search
Ahmed Younes (talk | contribs) No edit summary |
Ahmed Younes (talk | contribs) No edit summary |
||
| Line 2: | Line 2: | ||
{{Microsporidiosis}} | {{Microsporidiosis}} | ||
{{CMG}};{{AE}}{{AY}} | {{CMG}};{{AE}}{{AY}} | ||
==Overview== | |||
Secondary prevention strategies following microsporidiosis include continuing treatment indefenitely after ocular microsporidiosis and continued HAART for HIV patients. | |||
==Secondary Prevention== | ==Secondary Prevention== | ||
===Prevention of Recurrence=== | ===Prevention of Recurrence=== | ||
Treatment for ocular microsporidiosis should be continued indefinitely because recurrence or [[relapse]] might follow treatment discontinuation ('''BIII'''). Whether treatment can be safely discontinued after immune restoration with [[ART]] is unknown, although it is reasonable, on the basis of the experience with discontinuation of secondary prophylaxis (chronic maintenance therapy) for other opportunistic infections during advanced HIV-1 disease, to discontinue chronic maintenance therapy if patients remain asymptomatic with regard to signs and symptoms of microsporidiosis and have a sustained (e.g. >6 months) increase in their [[CD4+ T lymphocyte]] counts to levels >200 cells/µL after [[ART]] ('''CIII'''). | *Treatment for ocular microsporidiosis should be continued indefinitely because recurrence or [[relapse]] might follow treatment discontinuation ('''BIII'''). | ||
*Whether treatment can be safely discontinued after immune restoration with [[ART]] is unknown, although it is reasonable, on the basis of the experience with discontinuation of secondary prophylaxis (chronic maintenance therapy) for other opportunistic infections during advanced HIV-1 disease, to discontinue chronic maintenance therapy if patients remain asymptomatic with regard to signs and symptoms of microsporidiosis and have a sustained (e.g. >6 months) increase in their [[CD4+ T lymphocyte]] counts to levels >200 cells/µL after [[ART]] ('''CIII'''). | |||
==References== | ==References== | ||
Revision as of 20:49, 2 July 2017
|
Microsporidiosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Microsporidiosis secondary prevention On the Web |
|
American Roentgen Ray Society Images of Microsporidiosis secondary prevention |
|
Risk calculators and risk factors for Microsporidiosis secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Ahmed Younes M.B.B.CH [2]
Overview
Secondary prevention strategies following microsporidiosis include continuing treatment indefenitely after ocular microsporidiosis and continued HAART for HIV patients.
Secondary Prevention
Prevention of Recurrence
- Treatment for ocular microsporidiosis should be continued indefinitely because recurrence or relapse might follow treatment discontinuation (BIII).
- Whether treatment can be safely discontinued after immune restoration with ART is unknown, although it is reasonable, on the basis of the experience with discontinuation of secondary prophylaxis (chronic maintenance therapy) for other opportunistic infections during advanced HIV-1 disease, to discontinue chronic maintenance therapy if patients remain asymptomatic with regard to signs and symptoms of microsporidiosis and have a sustained (e.g. >6 months) increase in their CD4+ T lymphocyte counts to levels >200 cells/µL after ART (CIII).